期刊
CLINICAL INFECTIOUS DISEASES
卷 55, 期 8, 页码 1047-1055出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis616
关键词
-
资金
- CDC Foundation
- Abbott Laboratories
- Genentech
- Janssen Pharmaceutical Companies of Johnson Johnson
- Vertex Pharmaceuticals
- Abbott Pharmaceuticals
- Anadys Pharmaceuticals
- Bristol-Myers Squibb
- Conatus
- Eiger Biopharmaceuticals, Inc
- Exalenz BioScience
- Gilead Pharmaceuticals
- GlaxoSmithKline
- GlobeImmune
- Intercept Pharmaceuticals
- Merck
- Roche Pharmaceuticals
- Tibotec
- Zymogenetics
- Henry Ford Health System
- NIH
Background. Little is known about viral hepatitis testing and infection prevalence among persons in private healthcare organizations (HCOs) in the United States. Methods. To determine the frequency of and characteristics associated with viral hepatitis testing and infection prevalence among adults with access to care, we conducted an observational cohort study among 1.25 million adults from 4 US HCOs and included persons with >= 1 clinical encounter during 2006-2008 and >= 12 months of continuous follow-up before 2009. We compared the number of infections identified with the number expected based on adjusted data from the National Health and Nutrition Examination Survey (NHANES). Results. Of 866 886 persons without a previous hepatitis B virus (HBV) diagnosis, 18.8% were tested for HBV infection, of whom 1.4% tested positive; among 865 659 without a previous hepatitis C virus (HCV) diagnosis, 12.7% were tested, of whom 5.5% tested positive. Less than half of those with >= 2 abnormal alanine aminotransferase (ALT) levels were subsequently tested for HBV or HCV. When tested, Asians (adjusted odds ratio [aOR] 6.33 relative to whites) were most likely HBV infected, whereas those aged 50-59 years were most likely HCV infected (aOR 6.04, relative to age <30 years). Based on estimates from NHANES, nearly one-half of HCV and one-fifth of HBV infections in this population were not identified. Conclusions. Even in this population with access to care and lengthy follow-up, only a fraction of expected viral hepatitis infections were identified. Abnormal ALT levels often but not consistently triggered testing. These findings have implications for the identification and care of 4-5 million US residents with HBV and HCV infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据